ALL-IN-ON-GREEN
12.12.2022 07:01:35 CET | Business Wire | Press release
At least 70 cities in Europe can now prevent huge amounts of waste from ending up in the sea. This has been demonstrated in the city of Aarhus in Denmark, where the robot SeaProtectorOne, made by All In On Green, collected over 100,000 pieces of waste from the city’s river in just 20 months. The technology thus shows how much pollution the city is otherwise sending into the marine environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221211005006/en/
Many tonnes of waste flow into the sea from the world’s rivers: A Danish robot minimises this pollution (Photo: Business Wire)
Once waste enters the oceans, removing it is extremely difficult. This is why a Danish robotics invention is tackling the problem before it happens. The robot SeaProtectorOne is installed at the river mouth in Aarhus, where the river flows into the harbour and wider sea. The robot collects the waste—things like plastic cups, facemasks and pizza boxes—before it pollutes the sea. At the same time, it allows boats and other marine vessels to pass by.
SeaProtectorOne could also limit sea pollution from rivers in at least 70 other cities in Europe. This potential has been shown by thorough studies of the cities’ local conditions carried out by the team that has developed SeaProtectorOne. Kim Gulvad Svendsen, COO, Aarhus Municipality, readily shares his positive experience with this new weapon in the fight to prevent sea pollution.
“After the trial period, we were surprised at just how effective the robot was and by how much waste – especially plastic – it removed. This is plastic that will no longer end up in our marine environment. So the robot supports Aarhus Municipality’s sustainability efforts and above all, the UN’s global sustainable development goal no. 14: Life Below Water,” said Kim Gulvad Svendsen.
Every year, the amount of plastic waste that ends in the oceans is equivalent in weight to 57,000 blue whales. At least 90% of the plastic waste that floats around in the oceans, ends in the sea via river systems, according to the periodical Environmental Science.
“Once waste enters the sea it spreads quickly and is difficult to collect. Whereas the current in a river allows for the systematic filtering of waste in a limited area without disturbing fish or birds,” said Peter Grønkjær, Professor of Marine Biology at the Aarhus University.
Mads Tranders Nielsen from All In On Green is the man who invented SeaProtectorOne.
“In an ideal world, every citizen everywhere would learn to always put waste into a waste bin. But we don’t live in an ideal world. The idea for the robot came to me when I saw huge amounts of waste floating in a river in Melbourne. SeaProtectorOne has now shown its worth, even in Aarhus, one of Europe’s greenest cities. So, I’m looking forward to bringing this technology to the rest of the world for the benefit of the marine environment, fish and birds,” said Mads Tranders Nielsen from All In On Green.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221211005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom